Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug

J Neuroimmunol. 2008 Oct 15;203(1):73-8. doi: 10.1016/j.jneuroim.2008.06.039.

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated, autoimmune disease of the central nervous system (CNS) that serves as a model for various cellular and molecular aspects of the human disease, multiple sclerosis (MS). Although EAE has long been considered a T cell-mediated disease, macrophages play a role in disease pathogenesis and are known to accumulate in the CNS under the control of chemokines. In the present report we demonstrate that mice induced to develop EAE were treated with a small molecular weight molecule that suppresses proinflammatory cytokine production which resulted in significantly decreased clinical EAE, CNS CCL2 expression and CNS macrophage accumulation. These results demonstrate the efficacy of a novel class of therapeutic molecules for CNS demyelinating disease.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Blood-Brain Barrier / metabolism
  • Cell Movement / immunology
  • Chemokine CCL2 / antagonists & inhibitors*
  • Chemokine CCL2 / chemistry
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Encephalomyelitis, Autoimmune, Experimental / immunology*
  • Female
  • Macrophages / pathology
  • Mice
  • Molecular Weight
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / immunology
  • Pyridazines / pharmacology*
  • Pyrimidines / pharmacology*
  • Severity of Illness Index

Substances

  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Pyridazines
  • Pyrimidines
  • minozac